No abstract

No abstract

No abstract

every 2 months to a maximum of 100 mg/day. He noted clinical improvement with 1 5 mg, but said it was less rapid than that with 50 and 100 mg/day. However, the clinical picture is not generally considered to be consistent enough to allow such fine discrimination in drug response, and in most clinical trials it has been found necessary to assess the drug by the bacteriologic response in groups of lepromatous cases, each group on a particular dosage for a year or more.Thus it seems indicated to test the therapeutic effect in human leprosy of lower dosages of DDS and less frequent administration.The margin between toxic level and therapeutic level of the drug appears to be so large as to allow considerable innovation in the regimen. DDS is excreted only slowly and Ross ( 15) has reported detectable concentrations in blood 2 to 4 weeks after the last administration of sulfone. The results suggest that DDS might have an especially useful role in chemoprophylaxis, a contra1 measure potentially adaptable to many leprosy endemic areas.Summary. 1. The activity against Mycobacterium Zeprae of 4,4'-diaminodiphenyl sulfone (DDS) was tested in mice by feeding a series of diets containing the drug in concentrations ranging from 0.03 to 0.00001%. Multiplication of M . Zepae was completelysuppressed a t all levels. 2. The lowest DDS intake was a hundred times less that the least amount required to produce chemically detectable amounts in the blood (0.2 to 0.3 p,Lg/ml) * 1. Lowe, J., Leprosy Rev., 1954, v25, 113.

No abstract